TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01885260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-GCGRRx - Dose Level 1
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-GCGRRx - Dose Level 2
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses on alternate days during the first week and then once weekly for 12 weeks
Study: NCT02995902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLT-PET

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study: NCT03911453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
Study: NCT03968315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragm Fluoroscopy
Description: Undergo diaphragm fluoroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04000594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7234292 (RG6042)
Description: RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
Study: NCT02204579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPSP795
Study: NCT02541214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trial Nasal Mask
Study: NCT02543190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: compliance surveillance and improvement strategy
Description: External monitor to ensure compliance with an educational protocol.
Study: NCT04301440

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The emission of electromagnetic with the probes
Description: The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The emission of electromagnetic without the probes
Description: The patient will be in the lying position, a probe will be positioned in the middle of the chest and the second probe below the xyphoid. The probes will be fixed by a band to keep them in place. The emission of electromagnetic waves is painless.
Study: NCT01755624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100A device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care
Study: NCT02911350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone Suppressors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study: NCT03926793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002
Description: GB002 low dose or high dose for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002
Description: GB002 low dose or high dose for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB002
Description: GB002 low dose or high dose for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 or Placebo delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 or Placebo delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Generic Dry Powder Inhaler
Description: Generic dry powder inhaler for GB002 or Placebo delivery
Study: NCT00856661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: 90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV, single bolus over 1 to 2 minutes on 1st day
Study: NCT01800695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-414
Description: ABT-414 will be administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered per label and local prescribing regulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be administered per label and local prescribing regulations.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation
Description: Whole Brain radiation will be administered in 30 fractions.
Study: NCT01704911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transradial Coronary Intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transfemoral Coronary Intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Stent System
Description: Any kind of coronary stent system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Stent System
Description: Any kind of coronary stent system
Study: NCT01233583

Intervention type: DRUG
Intervention: Dovobet, neotigason, etanercept, adalimumab. infliximab
Description: Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks

Intervention type: DRUG
Intervention: Dovobet, neotigason, etanercept, adalimumab. infliximab
Description: Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks

Intervention type: DRUG
Intervention: Dovobet, neotigason, etanercept, adalimumab. infliximab
Description: Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks

Intervention type: DRUG
Intervention: Dovobet, neotigason, etanercept, adalimumab. infliximab
Description: Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
Study: NCT00486135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Gelatin capsules supplied in 25-mg and 100-mg dosage strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Gelatin capsules supplied in 25-mg and 100-mg dosage strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
Study: NCT01925027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano+ DES
Description: All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
Study: NCT03556358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TX05 (trastuzumab)
Description: 8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: 8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
Study: NCT02676908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression socks for 2 weeks
Description: Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression socks for 2 weeks
Description: Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
Study: NCT00594971

Intervention type: OTHER
Group type: OTHER
Intervention: Organisational intervention
Description: A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.

Intervention type: OTHER
Group type: OTHER
Intervention: Referral to a specialist palliative care team.
Description: Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
Study: NCT01298921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: 100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
Study: NCT02592200

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri DSM 27123
Description: 109 CFU (divided in two doses) per day for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses per day for 28 days
Study: NCT00399763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
Study: NCT02681705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Craniospinal Radiation
Description: Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
Study: NCT00780182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX001
Description: CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
Study: NCT03515057

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Single lead handheld electrocardiogram
Description: Screening for atrial fibrillation during outpatient primary care office visits among patients 65 years and older
Study: NCT03904511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Souroubea-Platanus Preparation
Description: Extracts of S. Sympetala and P. occidentalis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Souroubea-Platanus Preparation
Description: Extracts of S. Sympetala and P. occidentalis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03908073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: The use of a transcutaneous vagal nerve stimulator by the participant

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: The use of a transcutaneous vagal nerve stimulator by the participant
Study: NCT02260505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib maintenance
Description: Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
Study: NCT02638623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: 2L Lactated Ringer administered prior to primary knee or hip arthroplasty

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No additional fluids will be administered
Study: NCT03761134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT05728567

Intervention type: OTHER
Intervention: whether the participants had T2DM
Description: whether the participants had T2DM

Intervention type: OTHER
Intervention: whether the participants had T2DM
Description: whether the participants had T2DM
Study: NCT00256854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 1 mg Placebo
Description: Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 1 mg Placebo
Description: Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg Placebo
Description: Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg Placebo
Description: Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg Placebo
Description: Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole IR 2 mg Placebo
Description: Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
Study: NCT03761134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00256854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2 mg
Description: Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2 mg
Description: Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 3 mg
Description: Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 3 mg
Description: Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.
Study: NCT02205801

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Cervical Plexus Block
Description: 0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superficial Cervical Plexus Block
Description: 0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Wound Infiltration
Description: 0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Local Wound Infiltration
Description: 0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Study: NCT00256854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 3 mg
Description: Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 3 mg
Description: Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2 mg Placebo
Description: Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 2 mg Placebo
Description: Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 3 mg Placebo
Description: Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole CR 3 mg Placebo
Description: Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.
Study: NCT03761134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04596826

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 5 MG
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 5 MG
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol 5 MG
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronabinol 5 MG
Description: oral administration